Metraipolis › archive › dc_da8472a19c71

Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI — Europe PMC PMID:42813964

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42813964
DOI
10.1111/liv.70888
License (as archived)
solo-consultazione
Archived
2026-10-06T18:02:06.712Z
SHA-256 of the archived text
a59cdbdb937655dc39107e7e68c4db273f22ac43ccace238babf303f88ade183
Stable URL of this page
https://metraipolis.com/documento/dc_da8472a19c71

How to cite

Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI — Europe PMC PMID:42813964 — Europe PMC (en), https://europepmc.org/article/MED/42813964 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da8472a19c71 (Metraipolis archive dc_da8472a19c71, sha256 a59cdbdb937655dc39107e7e68c4db273f22ac43ccace238babf303f88ade183)
BibTeX
@misc{dcda8472a19c71,
  title = {Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI — Europe PMC PMID:42813964},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42813964},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da8472a19c71; sha256 a59cdbdb937655dc39107e7e68c4db273f22ac43ccace238babf303f88ade183},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42813964. Agents can read the archived copy with the MCP tool read_document.